CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection.
Naturally occurring CD4+CD25+ regulatory T cells (Tregs) play a critical role in the control of periphery tolerance to self-antigens. Interestingly, they also control immune responses to allergens and transplant antigens. Recent studies in animal models have shown that adoptive transfer of CD4+CD25+ Tregs can prevent or even cure allergic and autoimmune diseases, and appear to induce transplantation tolerance. Thus, adoptive cell therapy using patient-specific CD4+CD25+ Tregs has been emerged as individualized medicine for the treatment of inflammatory disease including allergy, autoimmune disease and transplant rejection. Furthermore, strategies to activate and expand antigen-specific CD4+CD25+ Tregs in vivo using pharmacological agents may represent a novel avenue for drug development.
Jiang
Shuiping
S
Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London, Guy's Hospital, London SE1 9RT, UK. shuiping.jiang@kcl.ac.uk
Lechler
Robert I
RI
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy*; D051927:CD24 Antigen / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy*; D007167:Immunotherapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D051927:CD24 Antigen